STK11 mutation status is associated with decreased survival in meningiomas.

<bold>Background: </bold>Emerging evidence suggests that STK11 mutations may influence clinical outcome and response to immunotherapy in cancer.<bold>Materials and Methods: </bold>Next-generation targeted sequencing of STK11 mutation status in a large cohort of 188 meningiomas.<bold>Results: </bold>STK11 loss-of-function mutations were identified in 3.7% of meningiomas. STK11 mutations were found in both low- and high-grade lesions and samples from primary and recurrent disease. There was a 2.8-fold increased risk of death for patients whose meningioma harbored an STK11 mutation, after controlling for lesion grade and occurrence status. The median overall survival for patients with STK11-mutated meningiomas was 4.4 years compared with 16.8 years.<bold>Conclusion: </bold>These data identify recurrent STK11 mutations in a subset of meningiomas. Genotyping of STK11 is encouraged for meningioma patients undergoing immunotherapy-based therapy. [ABSTRACT FROM AUTHOR]